We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Signet Announces the Availability of Monoclonal Prion Antibody 6D11

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Signet Announces the Availability of Monoclonal Prion Antibody 6D11"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Signet Laboratories, Inc. has announced the availability of Monoclonal Prion Antibody 6D11.

Prion diseases, or Transmissible Spongiform Encephalopathies (TSE), are degenerative diseases of the nervous system caused by transmissible particles that contain a pathogenic isoform of the prion protein, a normal constituent of cell membranes.

Although cross- species transmission of prion diseases seems to be limited by a “species barrier,” the occurrence of bovine spongiform encephalopathy (BSE) and its transmission to humans indicate that animal prion diseases can pose a significant public health risk.

“The development of highly sensitive assays for ante mortem detection of misfolded prions is a top priority for minimizing the spread of the disease,” stated Joe Bertelsen, Neuroscience Product Manager for Signet Laboratories.

“Signet's new 6D11 antibody, in addition to Signet's existing prion antibody panel, gives researchers a powerful tool for developing such screening systems.”